The brain has a volume knob for inhibition. Its name is KCC2. This company is trying to turn it - and treat epilepsy, chronic pain and disorders that have resisted decades of medicine.
In the crowded landscape of neuroscience drug discovery, most therapies work by suppression - dampening overactive neurons with blunt chemistry. Axonis Therapeutics is chasing a harder and more elegant idea: restore the brain's own ability to inhibit itself. The company, founded in 2020 and headquartered in Boston, builds oral medicines around a single molecular target called KCC2, a potassium-chloride cotransporter that sits at the center of how neurons quiet down.
When KCC2 works properly, it keeps chloride balance in neurons tuned so that inhibitory signals land as intended. When it under-performs - a state researchers call KCC2 hypofunction - the brain's brakes weaken. That single failure mode shows up across a surprising range of conditions: epilepsy, chronic pain, and certain neurodevelopmental disorders. Axonis' thesis is that a drug capable of potentiating KCC2 could address the root of neural disinhibition rather than merely masking its symptoms.
The science did not begin as a company. It began as a genome-wide AAV-CRISPR screen in the lab of Professor Zhigang He at Boston Children's Hospital and Harvard Medical School - an experiment designed to find genes that protect and regenerate neurons after central nervous system injury. Two of those researchers, Shane Hegarty and Joanna Stanicka, recognized that the biology pointed toward something druggable. In 2020 they spun the work out, with contributions from Universite Laval, and Axonis was born.
“As we head into the clinic, this financing is a significant milestone for Axonis as we translate our exciting science into efficacious and well-tolerated treatments.”
Every thought depends on a balance between excitation and inhibition. KCC2 is the transporter that makes inhibition possible - and Axonis wants to strengthen it.
KCC2 pumps chloride out of neurons, setting the electrical gradient that lets inhibitory (GABAergic) signals actually calm a cell down.
In disease, KCC2 hypofunction weakens that gradient. Inhibition falters, circuits over-fire, and seizures or pain signals can take hold.
Axonis' oral small molecule, AXN-027, is designed to potentiate KCC2 - restoring the brake rather than forcing the brain into silence.
A first-in-class oral small molecule that potentiates KCC2, the major CNS chloride transporter. Advancing toward clinical proof of concept in epilepsy and chronic pain.
A proprietary drug-discovery platform built on KCC2 biology and in vivo phenotypic screening, generating next-generation compounds aimed at inhibitory neurotransmission.
Epilepsy - including refractory forms - chronic and neuropathic pain, and neurodevelopmental conditions where disinhibition plays a role.
Axonis has raised more than $127M since 2020, culminating in an oversubscribed Series A that drew both specialist and crossover investors.
Who it serves. As a clinical-stage developer, Axonis' ultimate beneficiaries are patients living with neurological disorders - and the neurologists and pain specialists who treat them. Its near-term stakeholders are the investors funding the science and the pharmaceutical partners who could one day help scale it.
The problem it solves. Millions of people with epilepsy do not achieve control with existing drugs, and chronic pain remains poorly served by therapies that are either ineffective or carry the burden of opioids. Axonis targets a mechanism upstream of symptoms.
How it differs. Rather than adding another channel-blocker or receptor modulator, Axonis works on KCC2 - a target the field long viewed as difficult to drug. Restoring inhibition, instead of forcing sedation, is a distinct paradigm, and doing it with an oral small molecule keeps the door open to broad, convenient use.
The business model. Axonis is a venture-backed biotech: it develops proprietary drug candidates funded by equity and non-dilutive grants, creating value by advancing its pipeline through clinical milestones toward partnership, licensing or commercialization.
The competition. Axonis sits among CNS-focused biotechs pursuing novel epilepsy, pain and neurodevelopmental mechanisms - from ion-channel and GABAergic players to non-opioid pain programs. Its differentiator is the KCC2 discovery engine and first-mover position on the target.
The expertise. The team blends academic neuroscience pedigree - Boston Children's, Harvard, Laval - with drug-development experience, anchored by co-founders who were also the inventors of the underlying IP.
The company spins out of Boston Children's Hospital, Harvard and Universite Laval and announces seed financing for preclinical development of its neuromodulating KCC2 therapy.
Axonis expands its proprietary KCC2 discovery platform and preclinical programs around inhibitory neurotransmission.
Collaborative grants, including a SynGAP Research Fund award, back Axonis' work in neurodevelopmental disorders.
An oversubscribed Series A co-led by Cormorant and venBio funds the push of AXN-027 toward first-in-human studies.
“What the team has accomplished is remarkable. We are now well positioned to bring our lead therapeutic program through clinical proof of concept.”
“Axonis' scientists have done amazing work. We're very excited about what this program could mean for patients.”
“As we head into the clinic, this financing is a significant milestone for Axonis as we translate our exciting science into treatments.”
KCC2 sets the brain's inhibitory gain - a rare single target with relevance across epilepsy, pain and neurodevelopmental disease.
The founding science traces to a genome-wide AAV-CRISPR screen built to find genes that protect and regenerate injured neurons.
Two co-founders are University College Cork graduates, giving the Boston biotech a transatlantic academic lineage.
Curated searches for talks, interviews and program explainers from Axonis and its founders.
Axonis is a Boston-based biotechnology company developing oral small-molecule medicines that target KCC2, a chloride transporter central to the brain's inhibitory neurotransmission, for disorders including epilepsy and chronic pain.
AXN-027 is Axonis' lead development candidate - a first-in-class oral small molecule designed to potentiate KCC2 function, advancing toward clinical proof of concept in epilepsy and pain.
Axonis has raised more than $127M total, including an oversubscribed $115M Series A closed in October 2024, plus $34M+ in seed funding and $8M+ in non-dilutive grants.
Axonis was co-founded in 2020 by Joanna Stanicka (CEO), Shane Hegarty (CSO) and Corey Goodman (Executive Chair), spun out of research at Boston Children's Hospital, Harvard and Universite Laval.
KCC2 regulates chloride balance in neurons and is a key mediator of inhibitory signaling; its hypofunction is implicated across epilepsy, chronic pain and neurodevelopmental disorders, making it a potentially high-impact CNS target.